Stayble Therapeutics (STABL) Q1 2025 earnings summary

Executive summary

• Focused on advancing STA363, an injectable treatment for chronic disc herniation, with strong scientific and commercial interest.

• 100% subscription of TO2 warrants and a directed share issue in May secured capital, extending runway to Q2 2026.

• Ongoing partnership discussions with several mid- and large-cap pharma companies, leveraging positive phase 1b results.

• Scientific abstracts on STA363 accepted for major international conferences, highlighting clinical progress.

Financial highlights

• Operating costs for Q1 2025 were 2,066 KSEK, down from 3,908 KSEK in Q1 2024.

• EBIT for Q1 2025 was -2,044 KSEK, an improvement from -3,899 KSEK year-over-year.

• Net result for Q1 2025 was -2,044 KSEK, compared to -3,634 KSEK in Q1 2024.

• Cash and cash equivalents at period end were 2,570 KSEK, up from 2,195 KSEK at the start of the quarter.

• Share capital increased to 51,720,903 shares as of March 31, 2025, with a market cap of 30.8 MSEK.

Outlook and guidance

• Capital raised is intended to finalize partnership discussions, prepare phase 2b plans, and provide working capital through Q2 2026.

• Management anticipates continued strong interest in STA363 and aims to secure a partnership agreement based on phase 1b data.